OBIO Earnings Date: Nov 9, 2026 (Estimated) — Orchestra BioMed Holdings, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is OBIO's next earnings date?
Orchestra BioMed Holdings, Inc. (OBIO) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.40 on revenue of $129,429.
How did OBIO do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Orchestra BioMed Holdings, Inc. posted EPS of -$0.38 versus the -$0.39 estimate, a beat of 2.7%. Revenue was $88,000 against a $137,714 estimate. The stock's 1-day post-earnings move was -1.3%.
How much does OBIO stock move after earnings?
OBIO beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.1% (up or down) in the day after earnings.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.39 | -0.38 | -2.70% | $88,000 | ✅ Beat | -1.35% | +5.83% | +22.20% |
| 2026-05-12 | Q1 2026 | -0.43 | -0.33 | +23.26% | $110,000 | ✅ Beat | +0.00% | -1.48% | +0.25% |
| 2026-03-12 | Q4 2025 | -0.38 | 0.26 | +168.42% | $30.9M | ✅ Beat | -4.78% | -1.96% | -10.22% |
| 2025-11-10 | Q3 2025 | -0.41 | -0.40 | +2.44% | $861,000 | ✅ Beat | +8.47% | +9.26% | +23.55% |
| 2025-08-12 | Q2 2025 | -0.51 | -0.50 | +1.96% | $836,000 | ✅ Beat | -2.21% | -6.25% | -3.68% |
| 2025-03-31 | Q4 2024 | -0.43 | -0.43 | +0.00% | $253,000 | ➖ Inline | -24.30% | -33.88% | -30.61% |
| 2024-08-12 | Q2 2024 | -0.39 | -0.45 | -15.38% | $778,000 | ❌ Miss | -2.46% | +4.58% | -6.87% |
| 2024-05-13 | Q1 2024 | -0.41 | -0.38 | +7.32% | $620,000 | ✅ Beat | +13.04% | +13.70% | +72.61% |
Showing last 8 quarters.